PT - JOURNAL ARTICLE AU - C. TropÉ AU - J. Carl TI - Gestational trophoblastic tumors: cytostatic treatment response evaluated from hCG modelling AID - 10.1046/j.1525-1438.1993.03050265.x DP - 1993 Aug 01 TA - International Journal of Gynecologic Cancer PG - 265--270 VI - 3 IP - 5 4099 - http://ijgc.bmj.com/content/3/5/265.short 4100 - http://ijgc.bmj.com/content/3/5/265.full SO - Int J Gynecol Cancer1993 Aug 01; 3 AB - Five patients, three high risk and two medium risk, were allocated to a high dose methotrexate regimen. Surviving fractions of hCG-producing cells in high dose methotrexate were a factor of 3–10 times lower than the surviving cell fractions in the low dose regimen, indicating a biphasic dose-response relation for methotrexate. Medium risk patients were found to have an unacceptably high recurrence rate after methotrexate actinomycin-D therapy and should be treated with more intensive chemotherapy. It is recommended that drug dose should be corrected for body-volume in low risk regimes, to avoid drug resistance developing because of increased treatment time.